Imugene Ltd.
(ASX: IMU)

FACT SHEET
November 30, 2015

Market Data

Fiscal Year December
Industry Biotechnology
Market Cap A$14.6M
Price/Earning (ttm) N/A
Price/Book (mrq) 1.8x
Price/Sales (ttm) 22.9x
Insider Ownership 7.1%
Shares Outstanding 1.7B
Equity Float 961.8M
Avg. Volume (3 mo.) 1.2M
As of November 27, 2015

Income Statement Snapshot

Revenue (LFY) A$0.6M
Net Loss (LFY) (A$2.4M)

Balance Sheet Snapshot

Cash(LFY) A$5.0M
Debt (LFY) A$0.0M

*Includes proceeds from A$3.0 million equity raise.

Imugene (“Imugene,” “IMU,” or the “Company”) is an immune-oncology biopharmaceutical company developing HER2 positive gastric and breast cancer immunotherapies. The Company’s lead product is HER-Vaxx, a proprietary HER2 positive cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu. HER-2/new is a known and validated receptor over-expressed on various tumors including gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has successfully completed a Phase I study in patients with breast cancer and the next stage of development will be a Phase Ib/II study in patients with gastric cancer. Imugene’s corporate headquarters are located in Melbourne, Australia with the scientific team in Vienna, Austria.

Imugene’s current market cap of A$14.6 million is far below the average market cap of U.S. companies with early stage cancer trials. The Company is entering a Phase Ib/2a trial with its potential blockbuster drug for gastric cancer, which is the second leading cause of cancer death in the world. HER-Vaxx exhibited strong Phase I results in breast cancer and has a potentially superior mechanism of action as compared to earlier generation t-cell immunotherapies.

  • Next generation HER2 cancer immunotherapy therapy using B-cell peptides
    • Potentially superior to t-cell vaccines. HER-Vaxx induces the patient to produce its own antibodies against the target, as opposed to t-cell vaccines which produce antibodies from vaccines manufactured outside the body
    • This novel approach can cause immune memory, strengthening the immune system response over time
    • HER-Vaxx targets three sites (polyclonal response) as opposed to one (monoclonal response) site in currently approved HER2 therapies

  • Phase I results displayed a strong antibody and overall immune system response in a patient population in poorer condition than the typical target HER2 population
    • 8/10 patients developed anti-HER-2 antibodies, and the antibodies displayed potent anti-tumor activity
    • Positive, broad immune system response (increase in Th1 cytokines, increase in memory T & B cells post vaccination, decrease in T reg cells)
    • Positive results were seen in metastatic breast cancer patients; other HER2 vaccines have been approved for patients with early-stage breast cancer

  • Positive Phase I results provide the basis for a Phase Ib/II trial in HER2 positive gastric cancer
    • Projected to begin Phase 1b trial in 1H16, with results reported in late 1H17
    • Projected to begin randomized, controlled, double-blinded Phase II trial in 2H17, with results reported in 2H19

  • Gastric cancer is the second leading cause of cancer death worldwide (738,000 deaths, or 10.4% of cancer cases)

  • Novel mimotope technology platform allows IMU to reverse engineer any antibody and induce a potent antibody response to an identified oncology target
    • Four mimotopes (including two checkpoint blockades) to be complete by May 2016

Company Website

Investor Contact Info:
RedChip Companies, Inc.
1017 Maitland Center Commons Blvd.
Maitland, FL 32751
(407) 644-4256
www.redchip.com

 Disclosure

 

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President The NASDAQ Stock Market